Chemomab Therapeutics Ltd.
CMMB
$1.23
-$0.005-0.41%
NASDAQ
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 802.00K | 840.00K | 751.00K | 990.00K | 2.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.21M | 3.77M | 3.85M | 4.37M | 9.05M |
| Operating Income | -3.21M | -3.77M | -3.85M | -4.37M | -9.05M |
| Income Before Tax | -2.96M | -3.63M | -3.42M | -4.14M | -8.73M |
| Income Tax Expenses | -- | -- | -- | -55.00K | 21.00K |
| Earnings from Continuing Operations | -2.96M | -3.63M | -3.42M | -4.08M | -8.75M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.96M | -3.63M | -3.42M | -4.08M | -8.75M |
| EBIT | -3.21M | -3.77M | -3.85M | -4.37M | -9.05M |
| EBITDA | -3.20M | -3.75M | -3.83M | -4.35M | -9.03M |
| EPS Basic | -3.14 | -5.08 | -5.25 | -6.90 | -15.84 |
| Normalized Basic EPS | -0.10 | -0.16 | -0.16 | -- | -0.49 |
| EPS Diluted | -3.14 | -5.08 | -5.25 | -6.90 | -15.84 |
| Normalized Diluted EPS | -0.10 | -0.16 | -0.16 | -- | -0.49 |
| Average Basic Shares Outstanding | 18.86M | 14.30M | 13.01M | 11.82M | 11.05M |
| Average Diluted Shares Outstanding | 942.80K | 715.20K | 650.60K | 591.10K | 552.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |